Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Infertility in Males01:23

Infertility in Males

Male infertility affects millions of couples worldwide, arising from various factors that impact different stages of the reproductive process. An endocrine imbalance resulting from conditions like hypogonadism, Klinefelter syndrome, or pituitary disorders can disrupt hormone levels and reduce sperm production. Testicular defects, such as tumors, cryptorchidism, atrophic testes, abnormal sperm morphology, and low sperm count or motility, may arise due to genetic factors, structural...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Utilizing Micro-RNA-371a-3p for Recurrence Prediction in Clinical Stage I Testicular Cancer.

The oncologist·2026
Same author

MRI-based Response Assessment of Neoadjuvant Systemic Immunotherapy in Muscle-invasive Bladder Cancer: An Analysis of Inter-radiologist Variability and Diagnostic Accuracy in three Prospective Clinical Trials.

European urology oncology·2026
Same author

The Impact of Relative Dose Intensity on pCR in Neoadjuvant Chemotherapy of Muscle-Invasive Urothelial Cancer: a Multicentre Retrospective Study.

The oncologist·2026
Same author

Effectiveness and safety of avelumab maintenance in patients aged ≥75 years with advanced urothelial cancer: a sub-analysis of the meet-URO 25 (MALVA) study.

Frontiers in immunology·2026
Same author

Cystectomy Remains Standard of Care Following Neoadjuvant Therapy in Patients with Muscle-Invasive Bladder Cancer.

European urology·2026
Same author

Stereotactic radiosurgery and multimodal integration approaches for germ cell tumor brain relapse.

Journal of neuro-oncology·2026

Related Experiment Video

Updated: May 16, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

How to Optimize Treatment for Patients With Poor-Risk Testicular Cancer.

Noah Richardson1, Alok K Tewari2, Patrizia Giannatempo3

  • 1Division of Hematology & Medical Oncology-Melvin & Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|May 14, 2026
PubMed
Summary

Optimizing treatment for poor-risk male germ cell tumors is crucial. This review details systemic therapy, surgical evaluation, and multidisciplinary strategies to improve survival in this young patient population.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Experiment Videos

Last Updated: May 16, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Area of Science:

  • Oncology
  • Urology

Background:

  • Male germ cell tumors, primarily testicular cancer, are rare but highly curable malignancies.
  • While cure rates are high, poor-risk patients face suboptimal outcomes and significant mortality.
  • Identifying and managing poor-risk patients is vital for improving survival in this young demographic.

Purpose of the Study:

  • To review the current treatment landscape for poor-risk male germ cell tumors.
  • To highlight essential strategies for optimizing survival in this patient subgroup.
  • To emphasize the importance of a multidisciplinary approach in managing complex cases.

Main Methods:

  • Review of established first-line therapies and salvage systemic therapies.
  • Discussion of surgical evaluation for unique disease characteristics.
  • Analysis of treatment strategies for brain metastases and other clinical scenarios.

Main Results:

  • Poor-risk patients require specialized therapy selection and toxicity management.
  • Surgical evaluation is critical for addressing multifocal, mediastinal, and metastatic disease.
  • Salvage therapies offer options but demand expertise in patient selection and delivery.

Conclusions:

  • Optimizing survival in poor-risk male germ cell tumors necessitates expert management of systemic therapies and surgical interventions.
  • A multidisciplinary approach is essential for maximizing cure rates in this challenging patient group.
  • Continued research and refined strategies are needed to further improve outcomes for poor-risk patients.